Stockscreener 앱 받기
10.00
13.90%
1.22
시간 외 거래:
9.92
-0.08
-0.80%
전일 마감가:
$8.78
열려 있는:
$9.49
하루 거래량:
4.31M
Relative Volume:
0.61
시가총액:
$825.73M
수익:
-
순이익/손실:
$-314.85M
주가수익비율:
-2.7913
EPS:
-3.5825
순현금흐름:
$-283.27M
1주 성능:
+18.06%
1개월 성능:
+91.57%
6개월 성능:
+3.52%
1년 성능:
+5.21%
1일 변동 폭
$9.12
$10.40
1주일 범위
$8.25
$10.40
52주 변동 폭
$1.50
$13.24
레플리뮨 Stock (REPL) Company Profile
명칭
Replimune Group Inc
전화
(781) 222-9600
주소
500 UNICORN PARK, WOBURN, MA
Compare REPL vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
10.00 | 739.85M | 0 | -314.85M | -283.27M | -3.5825 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
레플리뮨 Stock (REPL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
| 2026-04-13 | 다운그레이드 | H.C. Wainwright | Buy → Sell |
| 2026-04-13 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2026-04-13 | 다운그레이드 | Jefferies | Buy → Hold |
| 2026-04-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2026-04-13 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2026-04-10 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-11-03 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2025-10-27 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-20 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-10-20 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2025-10-20 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2025-09-19 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-30 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-07-23 | 다운그레이드 | BMO Capital Markets | Outperform → Underperform |
| 2025-07-23 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-23 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-07-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-22 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-22 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2025-06-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2023-04-17 | 재개 | Piper Sandler | Overweight |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-10-15 | 재개 | BTIG Research | Buy |
| 2020-11-17 | 개시 | BTIG Research | Buy |
| 2020-11-02 | 개시 | Jefferies | Buy |
| 2020-10-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-07-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-05 | 개시 | Barclays | Overweight |
| 2019-09-04 | 개시 | ROTH Capital | Buy |
| 2019-07-23 | 개시 | Chardan Capital Markets | Buy |
| 2019-07-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-07-08 | 개시 | H.C. Wainwright | Buy |
| 2019-04-25 | 개시 | Wedbush | Outperform |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-08-14 | 개시 | JP Morgan | Overweight |
| 2018-08-14 | 개시 | Leerink Partners | Outperform |
모두보기
레플리뮨 주식(REPL)의 최신 뉴스
REPL Stock On Track To Hit All-Time Lows – Here’s Why This Analyst Slashed Price Target By 85% - Stocktwits
REPL nosedives as FDA chief stands firm against melanoma treatment: ‘I don’t work for Replimune’ - MSN
REPL Stock On Track For Worst Drop In Nearly 7 Months Ahead Of FDA Decision On Skin Cancer Drug - Stocktwits
Replimune Group Stock Short Interest Rises to 56.4% - Quiver Quantitative
REPL stock soars on plans of BLA resubmission for melanoma combo drug - MSN
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
Replimune: Modeling The Coin Flip Of FDA Approval - Seeking Alpha
Replimune CCO Sarchi sells $110,880 in stock By Investing.com - Investing.com South Africa
Insider Sell: Christopher Sarchi Sells 12,000 Shares of Replimune Group Inc (REPL) - GuruFocus
Replimune CCO Sarchi sells $110,880 in stock - Investing.com
Replimune (REPL) CCO sells 12,000 shares under 10b5-1 plan - Stock Titan
Replimune surges on plans to resubmit lead drug for FDA review - MSN
REPL Stock Shot Up 80% Today – What’s The Deal With FDA? - Stocktwits
REPL Maintains Rating by Wedbush -- Price Target Raised to $6.00 - GuruFocus
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug - Yahoo Finance
Replimune Group Price Target Raised to $6.00/Share From $2.00 by Wedbush - Moomoo
Replimune Group Is Maintained at Neutral by Wedbush - Moomoo
Why Is Replimune Stock Gaining Monday? - Benzinga
Replimune Group (REPL) Is Up 77.0% After FDA Prioritizes RP1 Melanoma BLA Resubmission PathHas The Bull Case Changed? - simplywall.st
Why is REPL stock gaining in pre-market today? - MSN
Why Is REPL Stock Gaining In Pre-Market Today? - Yahoo Finance
Replimune plans RP1 BLA resubmission - The Pharma Letter
Palomar Holdings, Replimune Group, Snowflake - TradingView
US FDA Consistency Questions Remain As Replimune Eyes Third Shot At RP1 Approval - Citeline News & Insights
JPMorgan upgrades Replimune stock rating on FDA resubmission path - Investing.com
JPMorgan upgrades Replimune stock rating on FDA resubmission path By Investing.com - Investing.com Australia
REPL Stock Quote Price and Forecast - CNN
Top Biotech Gainers: REPL On Track, SNSE Awaits Phase 2 Data, Keep An Eye On CCCC, IMRX Soars - RTTNews
REPL stock shot up 80% today – what’s the deal with FDA? - MSN
$Replimune (REPL.US)$ - Moomoo
Replimune (REPL) Reports Promising Survival Data from IGNYTE Tri - GuruFocus
Replimune (REPL) Reports Positive Data from RP2 Trials for Advan - GuruFocus
Replimune (REPL) Reports Positive Data from RP2 Trials for Advanced Tumors - GuruFocus
Replimune (REPL) Reports Promising Survival Data from IGNYTE Trial - GuruFocus
REPL Technical Analysis & Stock Price Forecast - Intellectia AI
Replimune Group Presents Final First-in-Human Data for RP2 Oncolytic Immunotherapy at ASCO 2026 - Quiver Quantitative
Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - The Manila Times
Replimune (REPL) Gains FDA Support for RP1 Resubmission - GuruFocus
Replimune Group Inc. has released the latest data on its candidate therapy Rp1 in combination with nivolumab, showing remarkable long-term survival benefits in patients with advanced melanoma who have developed resistance to PD-1 therapies, with a me - Bitget
Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting - The Daily Tribune News
Replimune Group Says Rp1 Plus Nivolumab Achieves Median Overall Survival Of 32.9 Months In Anti-Pd-1-Failed Melanoma - TradingView
Nearly half of anti-PD-1-failed melanoma alive 3 years with Replimune combo - Stock Titan
Replimune gets third chance at US approval for skin cancer drug | Business Information & News | FE - Westlaw Today
How Replimune's Drug Got Third Chance After White House Intervention -- WSJ - Moomoo
Exclusive | How Replimune’s Drug Got Third Chance After White House Intervention - WSJ
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks - BioPharma Dive
레플리뮨 (REPL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
레플리뮨 주식 (REPL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Xynos Konstantinos | Chief Medical Officer |
May 18 '26 |
Sale |
5.08 |
14,023 |
71,237 |
235,662 |
| Schwendenman Andrew | Chief Accounting Officer |
May 18 '26 |
Sale |
5.08 |
7,894 |
40,102 |
107,057 |
| Sarchi Christopher | Chief Commercial Officer |
May 18 '26 |
Sale |
5.08 |
8,626 |
43,820 |
192,962 |
| Astley-Sparke Philip | Director |
May 18 '26 |
Sale |
5.08 |
17,657 |
89,698 |
1,412,414 |
| Patel Sushil | Chief Executive Officer |
May 18 '26 |
Sale |
5.08 |
37,324 |
189,606 |
747,492 |
| Hill Emily Luisa | Chief Financial Officer |
May 18 '26 |
Sale |
5.08 |
7,812 |
39,685 |
236,556 |
| Sarchi Christopher | Chief Commercial Officer |
Apr 02 '26 |
Sale |
8.01 |
6,500 |
52,065 |
151,588 |
2.60%
0.94%
자본화:
|
볼륨(24시간):